AT\textsubscript{1} Receptor Blockade and Atherosclerosis
Hopeful Insights Into Vascular Protection

Douglas E. Vaughan, MD

Angiotensin II (Ang II) is a potent vasoconstrictor, and apart from its effects on blood pressure, this short-lived peptide has been strongly implicated in the pathogenesis of ischemic cardiovascular disease. At the molecular and cellular levels, Ang II promotes a complex array of effects that may promote the initiation and progression of atherosclerosis.

See p 1586

At each of the well-defined stages of atherosclerosis, Ang II has the potential to contribute to the vascular pathobiology. For example, type 1 atherosclerotic lesions are defined by the presence of increased numbers of macrophages in the vascular intima and by the formation of foam cells.\textsuperscript{1} At this early stage of atherosclerosis, Ang II facilitates the recruitment of monocytes/macrophages into the vessel wall by stimulating the production of monocyte chemoattractant protein\textsuperscript{2} and vascular cell adhesion molecule-1\textsuperscript{3} by smooth muscle cells. Once monocytes are localized to the blood vessel wall, these cells undergo a phenotypic transformation and take up oxidized LDL, leading to foam cell formation. Ang II indirectly facilitates this step by activating membrane-based NADP/NADPH oxidase,\textsuperscript{4} which promotes the production of superoxide radicals (O\textsubscript{2}\textsuperscript{–}). The oxidant stress triggered by Ang II may contribute to enhanced oxidation of LDL and degradation of nitric oxide (NO). The loss of NO has many vascular biological ramifications, because NO is widely considered a vascular protective molecule that retards the development of atherosclerosis.\textsuperscript{5} Within the last 2 years, a new receptor, biochemically distinct from the scavenger receptor, has been identified that mediates the binding and uptake of oxidized LDL (oxLDL) by vascular tissue.\textsuperscript{6} The expression of this oxLDL receptor has recently been shown to be regulated by Ang II,\textsuperscript{7} and this may contribute to endothelial dysfunction and to accumulation of lipid in atherosclerotic plaques. Later stages of atherosclerosis are characterized by increased smooth muscle cell content, increased matrix deposition, and the accumulation of fibrinogen and fibrin in the plaque.\textsuperscript{8} The pluriptotent peptide Ang II likely contributes to all of these processes as well. Ang II is a well-characterized mitogen for vascular smooth muscle cells and stimulates the accumulation of extracellular matrix directly and indirectly by stimulating the production of transforming growth factor-β.\textsuperscript{9} Studies from this laboratory and others have shown that Ang II can promote the production of plasminogen activator inhibitor-1 in vascular tissue.\textsuperscript{10,11} This leads to reduced efficiency of the fibrinolytic system and likely contributes to the deposition of fibrin and fibrinogen typically seen in the late stages of atherosclerosis.

Many of the proatherosclerotic effects of Ang II are mediated by the binding of the peptide to the type 1 angiotensin (AT\textsubscript{1}) receptor. In this issue of Circulation, Strawn and colleagues\textsuperscript{12} describe the effects of the AT\textsubscript{1} receptor antagonist losartan on the development of atherosclerosis in cholesterol-fed cynomolgus monkeys. Animals were fed an atherogenic diet for a total of 20 weeks. Starting in week 12 of the study, animals were randomly assigned treatment to losartan or vehicle control delivered by osmotic minipumps implanted subcutaneously. At the end of the study period (20 weeks), the animals were killed, and the extent of atherosclerosis was determined by classic methods. Losartan had a consistent effect on reducing the extent of fatty streak formation by \textasciitilde 50\% in the aorta. The coronary arteries of losartan-treated animals also exhibited reduced arterial thickness. This reduction in the development of vascular pathology was not attributable to a decrease in plasma cholesterol. Furthermore, although losartan is primarily used for the treatment of hypertension in humans, these rather dramatic effects on the extent of fatty streak formation were not accompanied by a reduction in blood pressure in losartan-treated animals.

The present study confirms and extends prior observations made in a variety of experimental models indicating that interruption of the renin-angiotensin system can forestall the development of atherosclerosis. This was first shown with the ACE inhibitor captopril in Watanabe heritable hyperlipidemic rabbits.\textsuperscript{13} Subsequently, similar results have been reported in other animal models of atherosclerosis, including genetically modified mice,\textsuperscript{14} as well as rabbits\textsuperscript{15} and monkeys\textsuperscript{16} fed an atherogenic diet. The present study suggests that AT\textsubscript{1} receptor blockade blunts the development of atherosclerosis in the absence of a blood pressure–lowering effect. This finding contradicts prior studies in rabbits\textsuperscript{17} indicating that the antiatherosclerotic effects of ACE inhibition or AT\textsubscript{1} receptor blockade were dependent on blood pressure reduction. The reasons for this discrepancy are unclear but may reflect differences in animal models, pharmacological properties of the agents used, or other unidentified factors. It
suggests that in primates, Ang II plays a role in atherosclerosis in the absence of hypertension.

If the same relationship holds true in humans, then we might expect to see clinical benefits from ACE inhibitors and AT_1_ receptor blockers in the prevention of ischemic cardiovascular events. Certainly, the Survival And Ventricular Enlargement (SAVE) trial suggested that AT_1_ receptor blockade retards the development of atherosclerosis in humans deserve to be performed.

**References**


AT1 Receptor Blockade and Atherosclerosis: Hopeful Insights Into Vascular Protection
Douglas E. Vaughan

Circulation. 2000;101:1496-1497
doi: 10.1161/01.CIR.101.13.1496

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2000 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/101/13/1496

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/